Back to Results
Brentuximab Vedotin and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Hodgkin Lymphoma
||A Randomized Phase III Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents
Lymphomas, Hodgkin Lymphoma
||Michael J. Kelly, MD
This randomized phase III trial studies brentuximab vedotin and combination chemotherapy to see how well they work compared to combination chemotherapy alone in treating younger patients with newly diagnosed Hodgkin lymphoma.
- Subjects must have newly diagnosed, pathologically confirmed diagnosed Hodgkin lymphoma
- Must have liver function that is normal for age
- All subjects and/or their parents or legal guardians must sign a written informed consent
- Subjects with an immunodeficiency that existed prior to diagnosis, such as primary immunodeficiency syndromes, organ transplant recipients and children on current systemic immunosuppressive agents are not eligible
- Subjects who have received any previous chemotherapy or radiation therapy are not eligible
- Subjects who have received steroids within 28 days of beginning protocol treatment are not eligible
Therapy will be given over 5, 21-day cycles. Various infusions will be performed each cycle. A CT will be performed prior to Cycle 3 and after Cycle 5. A PET scan will also be performed at baseline and again at Cycle 2. A bilateral bone marrow biopsy will be taken at baseline and during Cycles 2 and 5 if the first is positive in Stage IV subjects. Finally, a complete CBC will be performed at baseline and prior to each cycle.
There is an optional biology study that will require various biopsies and blood draws that will be taken throughout the study.
Are you interested in learning more about this clinical trial?
Send us a message and we'll get back to you with more information.